Cabotegravir
CAS No. 1051375-10-0
Cabotegravir ( S/GSK1265744;GSK 744; Cabotegravir )
Catalog No. M17126 CAS No. 1051375-10-0
Cabotegravir (GSK744, GSK1265744) is a long-acting HIV integrase inhibitor and inhibits the HIV-1 integrase catalyzed strand transfer reaction (IC50: 3.0 nM).
Purity : 98%
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
10MG | 41 | In Stock |
|
25MG | 80 | In Stock |
|
50MG | 142 | In Stock |
|
100MG | 178 | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCabotegravir
-
NoteResearch use only, not for human use.
-
Brief DescriptionCabotegravir (GSK744, GSK1265744) is a long-acting HIV integrase inhibitor and inhibits the HIV-1 integrase catalyzed strand transfer reaction (IC50: 3.0 nM).
-
DescriptionCabotegravir, also known as S/GSK1265744 or GSK744, is potent HIV integrase inhibitor under development for the treatment of HIV infection. Cabotegravir has a carbamoyl pyridone structure similar to dolutegravir.
-
SynonymsS/GSK1265744;GSK 744; Cabotegravir
-
PathwayOthers
-
TargetOther Targets
-
RecptorHIV integrase
-
Research AreaInfection
-
Indication——
Chemical Information
-
CAS Number1051375-10-0
-
Formula Weight405.35
-
Molecular FormulaC19H17F2N3O5
-
Purity98%
-
SolubilityDMSO : 12.67 mg/mL 31.26 mM;
-
SMILESC[C@H]1CO[C@H]2N1C(=O)c1c(c(=O)c(cn1C2)C(=O)NCc1c(cc(cc1)F)F)O
-
Chemical Name(3S,11aR)-N-(2,4-difluorobenzyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Yoshinaga T, et al. Antimicrob Agents ChemOthers. 2015, 59(1), 397-406.
molnova catalog
related products
-
AS-604850
AS-604850 is a specific and ATP-competitive PI3Kγ inhibitor (IC50: 250 nM), 18-fold more selective for PI3Kγ than PI3Kα, and over 80-fold selectivity for PI3Kγ than PI3Kδ/β.
-
Isogambogenic acid
Isogambogenic acid inhibits angiogenesis and may be a viable drug candidate in anti-angiogenesis therapy.
-
Ginsenoside Rk3
Ginsenoside Rk3 and Rh4 could have a role in treating inflammatory diseases.